Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: A 2-year study

Current Medical Research and Opinion

Volumn 28, Issue 9, 2012, Pages 1435-1445

  Derosa, G ^a   D'Angelo, A ^a   Mugellini, A ^a   Pesce, R M ^a   Fogari, E ^a   Maffioli, P ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cardiovascular risk; Hypertension; Lipoprotein(a); Non conventional biomarkers; Treatment

Indexed keywords

ADVANCED GLYCATION END PRODUCT; APOLIPOPROTEIN A; BIOLOGICAL MARKER; CD40 LIGAND; LIPOPROTEIN A; MYELOPEROXIDASE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; HYPERTENSION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

APOPROTEIN(A); BIOLOGICAL MARKERS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 84866641326     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.717527     Document Type: Article

References (33)

1. Mancia G, Laurent S, Agabiti-Rosei E, et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
2. Fogari R, Zoppi A, Mugellini A, et al. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. Hypertens Res 2011;34:1321-6
3. Derosa G, Maffioli P, Ferrari I, et al. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res 2011;34:145-51
4. Derosa G, Maffioli P, Salvadeo SA, et al. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res 2010;33:790-5
5. Derosa G, Maffioli P, Salvadeo SA, et al. Candesartan effect on inflammation in hypertension. Hypertens Res 2010;33:209-13
6. Scanu AM, Scandian L. Lipoprotein (a): structure, biology and clinical relevance. Adv Intern Med 1991;36:249-70
7. Uterman G, Weber W. Protein composition of lipoprotein (a). J Clin Invest 1987;80:458-65
8. Geroldi D, Bellotti V, Buscaglia P, et al. Characterization of apo(a) polymorphism by a modified immunoblotting technique in an Italian population sample. Clin Chim Acta 1993;221:159-69
9. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993;143:1699-712
10. Graf D, Korthä uer U, Mages HW, et al. Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol 1992;22:3191-4
11. Morishita K, Kubota N, Asano S, et al. Molecular cloning and characterization of cDNA for human myeloperoxidase. J Biol Chem 1987;262:3844-51
12. Winer BJ. Statistical Principles in Experimental Design, 2nd edn. New York: McGraw-Hill, 1971
13. Emanuele E, Lusignani LS, Peros E, et al. Lipoprotein(a)-associated athero-thrombotic risk in hemodialysis patients. Am J Nephrol 2004;24:221-9
14. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998;82:57-66U
15. Glader CA, Birgander LS, Stenlund H, et al. Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med 2002; 252:27-35
16. Nordestgaard BG, Chapman MJ, Ray K, et al European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-53
17. Scanu AM. Lipoprotein(a). A genetic risk factor for premature coronary heart disease. JAMA 1992;267:3326-9
18. Serban C, Nicola T, Mateescu R, et al. Serum lipoprotein (a) levels in patients with arterial hypertension. Rev Med Chir Soc Med Nat Iasi 2010;114:798-802
19. Derosa G, Cicero AF, Gaddi A, et al. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 2003;25:1429-39
20. Derosa G, Mugellini A, Ciccarelli L, et al. Effects of fosinopril on blood pressure, lipid profile, and lipoprotein(a) levels in normotensive patients with type 2 diabetes and microalbuminuria: An open-label, uncontrolled study. Curr Ther Res Clin Exp 2002;63:216-26
21. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993;143:1699-712
22. Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267:14987-97
23. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004;63:582-92
24. Lindsey JB, Cipollone F, Abdullah SM, et al. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res 2009;6:7-14
25. Malherbe P, Richards JG, Gaillard H, et al. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res 1999;71:159-70
26. Falcone C, Emanuele E, D'Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondia-betic men. Arterioscler Thromb Vasc Biol 2005;25:1032-7
27. Koyama H, Shoji T, Yokoyama H, et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2005;25:2587-93
28. Geroldi D, Falcone C, Emanuele E, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005;23:1725-9
29. Ferroni P, Guadagni F. Soluble CD40L and its role in essential hypertension: diagnostic and therapeutic implications. Cardiovasc Hematol Disord Drug Targets 2008;8:194-202
30. Yuan M, Ohishi M, Wang L, et al. Association between serum levels of soluble CD40/CD40 ligand and organ damage in hypertensive patients. Clin Exp Pharmacol Physiol 2010;37:848-51
31. Penno G, Pucci L, Dell'Omo G, et al. Soluble CD40 ligand levels in essential hypertensive men: evidence of a possible role of insulin resistance. Am J Hypertens 2009;22:1007-13
32. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem 2000;275:37524-32
33. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002;296:2391-4